Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Abciximab (ReoPro) in Acute Ischemic Stroke: A Phase III, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled Trial.

NCT00073372 is registered in ClinicalTrials.gov with Centocor, Inc. as lead sponsor.

NCT NCT00073372
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00073372 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Abciximab (ReoPro) in Acute Ischemic Stroke: A Phase III, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled Trial.
Lead sponsor
Centocor, Inc.
Phase
Phase 3
Overall status
Terminated
Start date
October 31, 2003
Completion date
December 31, 2005
Enrollment
808 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

acute disease, brain ischemia, cerebrovascular accident